Select Language
COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global fertility services market size reached US$ 29.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 73.1 Billion by 2027, exhibiting a growth rate (CAGR) of 16% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Fertility services refer to the procedures provided as a treatment for infertility. Infertility is defined as the inability to conceive or carry a full-term pregnancy. Among males, it is identified by a low sperm count or is a result of hormonal imbalance in men. For females, infertility refers to the lack of proper functioning of glands such as hypothalamus and pituitary gland that stimulate hormones in the brain to trigger the ovaries to release an egg. Fertility treatments include medications and procedures that increase the chances of pregnancy. They involve fertility drugs, artificial insemination, In Vitro Fertilization (IVF), egg-freezing or oocyte cryopreservation, surrogacy, Assisted Reproductive Technology (ART) procedures, etc. They assist infertile couples, single parents and members of the LGBT community to plan a family.
www.imarcgroup.com
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
To get more information about this market, Request Sample
The expanding career-oriented population base has led to the increasing prevalence of delayed pregnancies, which is contributing significantly to the market growth. Owing to concerns such as expensive childcare services, academic or career ambitions, and a lack of financial stability, people often opt to have children late in life when they are more mature and financially established. However, excessive workload and the accompanying stress along with sedentary lifestyle habits including smoking and consumption of drugs lead to infertility issues among many of them. Moreover, the rising prevalence of various medical ailments such as endometrial tuberculosis, polycystic ovarian syndrome (PCOS) and sexually transmitted diseases (STDs) that can cause infertility, is also projected to catalyze the growth of the market. Additionally, growing awareness among individuals and increasing accessibility to improved healthcare facilities have further increased the adoption of these services in both developed and emerging economies. Other factors such as increasing advertising and promotion of fertility services on televisions and online portals along with the rising disposable incomes and flexible coverage offered by health insurance companies are also augmenting the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global fertility services market report, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on cause of infertility, procedure, service and end-user.
Breakup by Cause of Infertility:
www.imarcgroup.com
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
To get more information about this market, Request Sample
Breakup by Procedure:
Breakup by Service:
Breakup by End-User:
Breakup by Region:
www.imarcgroup.com
To get more information on the regional analysis of this market, Request Sample
The report has also analysed the competitive landscape of the market with some of the key players being Instituto Bernabéu Group, INVO Bioscience, Inc., Monash IVF Group, Apollo Hospitals Enterprise Ltd., CARE Fertility Group Ltd., Carolinas Fertility Institute, Genea Limited, The Cooper Companies, Inc., Virtus Health Group, Vitrolife Sweden AB, The Johns Hopkins Health System Corporation, Medicover AB (publ), OvaScience, Inc., Progyny, Inc., and Xytex Corporation, etc.
IMARC Group’s latest report provides a deep insight into the global fertility services market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the fertility services market in any manner.
Report Features | Details |
---|---|
Base Year of the Analysis | 2021 |
Historical Period | 2016-2021 |
Forecast Period | 2022-2027 |
Units | US$ Billion |
Segment Coverage | Cause of Infertility, Procedure, Service, End-User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Companies Covered | Instituto Bernabéu Group, INVO Bioscience, Inc., Monash IVF Group, Apollo Hospitals Enterprise Ltd., CARE Fertility Group Ltd., Carolinas Fertility Institute, Genea Limited, The Cooper Companies, Inc., Virtus Health Group, Vitrolife Sweden AB, The Johns Hopkins Health System Corporation, Medicover AB (publ), OvaScience, Inc., Progyny, Inc., and Xytex Corporation |
Customization Scope | 10% Free Customization |
Report Price and Purchase Option | Single User License: US$ 2499 Five User License: US$ 3499 Corporate License: US$ 4499 |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global fertility services market was valued at US$ 29.9 Billion in 2021.
We expect the global fertility services market to exhibit a CAGR of 16% during 2022-2027.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of numerous elective infertility treatments for reducing the risk of the coronavirus infection upon hospital visits, thereby negatively impacting the global market for fertility services.
The rising prevalence of delayed pregnancies, along with the increasing occurrences of various medical ailments, such as endometrial tuberculosis, PCOS, PCOD, STDs, etc., are primarily driving the global fertility services market.
Based on the cause of infertility, the global fertility services market has been divided into male infertility and female infertility, where male infertility currently exhibits a clear dominance in the market.
Based on the procedure, the global fertility services market can be categorized into In Vitro Fertilization with Intracytoplasmic Sperm Injection (IVF with ICSI), surrogacy, In Vitro Fertilization without Intracytoplasmic Sperm Injection (IVF without ICSI), Intrauterine Insemination (IUI), and others. Currently, In Vitro Fertilization with Intracytoplasmic Sperm Injection (IVF with ICSI) accounts for the majority of the total market share.
Based on the service, the global fertility services market has been segregated into fresh non-donor, frozen non-donor, egg and embryo banking, fresh donor, and frozen donor. Among these, fresh non-donor currently holds the largest market share.
Based on the end-user, the global fertility services market can be bifurcated into fertility clinics, hospitals, surgical centres, clinical research institutes, and cryobanks. Currently, fertility clinics exhibit a clear dominance in the market.
On a regional level, the market has been classified into Europe, North America, Asia Pacific, Middle East and Africa, and Latin America, where Asia Pacific currently dominates the global market.
Some of the major players in the global fertility services market include Instituto Bernabéu Group, INVO Bioscience, Inc., Monash IVF Group, Apollo Hospitals Enterprise Ltd., CARE Fertility Group Ltd., Carolinas Fertility Institute, Genea Limited, The Cooper Companies, Inc., Virtus Health Group, Vitrolife Sweden AB, The Johns Hopkins Health System Corporation, Medicover AB (publ), OvaScience, Inc., Progyny, Inc., Xytex Corporation, etc.
10% Free customization
Purchase Options
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at
sales@imarcgroup.com